Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)-phenyl-α-D-gluco- and mannopyranosides, p-(glutarylamido)-phphenyl-α-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-α-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>Code</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
</tr>
<tr>
<td>DE</td>
<td>Germany, Federal Republic of</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
</tr>
</tbody>
</table>

| GA   | Gabon                 |
| GB   | United Kingdom        |
| HU   | Hungary               |
| IT   | Italy                 |
| JP   | Japan                 |
| KP   | Democratic People's Republic of Korea |
| KR   | Republic of Korea     |
| LI   | Liechtenstein         |
| LK   | Sri Lanka             |
| LU   | Luxembourg            |
| MC   | Monaco                |
| MG   | Madagascar            |
| ML   | Mali                  |
| MR   | Mauritania            |
| MW   | Malawi                |
| NL   | Netherlands           |
| NO   | Norway                |
| RO   | Romania               |
| SD   | Sudan                 |
| SE   | Sweden                |
| SN   | Senegal               |
| SU   | Soviet Union          |
| TD   | Chad                  |
| TG   | Togo                  |
| US   | United States of America |
GLYCOSYLATED INSULIN DERIVATIVES

Background of the Invention

This invention relates to the preparation of glycosylated insulins. More particularly, this invention relates to the preparation of glycosylated insulins and to novel intermediates to be used in preparing glycosylated insulins.

Various systems have been proposed for the delivery of insulin to a diabetic patient that will be more responsive to the needs of the patient.

The bioengineering approach is directed towards design of insulin infusion pumps. Hundreds of diabetics presently use external battery-operated pumps. The pump injects insulin continuously through a needle attached to a catheter inserted into a vein or into subcutaneous tissue. The flow can be adjusted manually when a change occurs in the amount of insulin needed. The units are usually worn on a belt or strapped to a leg.

Still in an experimental stage are pumps that deliver an amount of insulin precisely determined by a sensor that measures blood glucose levels. Though successful progress has been made in this area, these pumps are still too heavy to be portable. Another difficulty is that the system needs an apparatus for the continuous sampling of blood, an analyzer to determine the blood glucose level rapidly and continuously, a computer to analyze the results and to determine the appropriate insulin dose, and an infusion pump to deliver insulin intravenously in a manner approximating the delivery by the beta cells of the pancreas. Efforts are underway to reduce the size of the system and prolong its sensor's life. A "vest pocket" model, a system the size
of a cigarette pack containing glucose sensor, power
source, computer, insulin reservoir and pump, has been
reported by Elliot in J. Am. Med. Assoc., 241, 223
(1979).

Another obstacle at present is the lack of an
accurate implantable electrode to sense the concentration
of blood glucose. Again, a through-the-skin connection
to the patient's blood stream for long periods presents
risks of infection and clotting problems. Also, the
occurring aggregation of insulin in the artificial
delivery systems poses a considerable problem since the
aggregated insulin will precipitate or crystallize out of
solution, thereby reducing the bioavailability of the
insulin in an insulin reservoir. In addition, the
aggregated insulin can become lodged in the delivery
needle and prevent the flow of insulin from the delivery
system to the diabetic.

**Objects and Summary of the Invention**

It is, therefore, an object of the present invention
to prepare a semisynthetic insulin which will not
aggregate as rapidly as native insulin and, therefore,
have a longer storage life.

It is also an object of the present invention to
prepare novel intermediate compounds to be used in the
preparation of non-aggregating semisynthetic insulins.

A still further object of the present invention is
to prepare glycosylated insulins which possess
significant biological activity in depressing blood sugar
levels.

These and other objects may be accomplished by means
of novel glycosylated insulins having one of the general
formulae:
insulin

and

insulin
where \( m \) is an integer of 1 to 3, \( X \) and \( Z \) are different and are selected from the group consisting of \(-\text{H}\) and \(-\text{OH}\) and \(-\text{Q}\) is a dicarboxylic acid spacer group having the formula:

\[
\begin{align*}
&\text{O} \\
&\text{C}-(\text{CH}_2)_n \text{Q} \\
&\text{C}
\end{align*}
\]

where \( n \) is an integer of from 2 to 6 and is preferably 2 or 3.

**Brief Description of the Drawings**

Figs. 1 through 4 of the drawings show elution profiles from chromatography tests as reported and further described in examples IX, X, XI and XII, respectively.

**Detailed Description of the Invention**

It is known that insulin can be combined with maltose as taught by Brownlee et al, in *Science*, 206, 223 (1979). However, this derivative of a disaccharide and insulin has been found not to possess any significant bioactivity in depressing blood sugar levels.

In the present invention, the intermediates prepared for coupling with insulin all consist of a glucose or mannose monosaccharide coupled to a spacer group. The spacer groups are derived from dicarboxylic acids, acid anhydrides or phenyl amines or a combination thereof. The intermediates have the following general formula:

![Chemical Structure]

\[
\begin{align*}
&\text{CH}_2\text{OH} \\
&\text{H} \\
&\text{H} \\
&\text{OH} \text{Z} \text{OY} \\
&\text{H} \\
&\text{H} \text{X}
\end{align*}
\]
wherein \( Y \) is a member selected from the group consisting of \( H, \quad \begin{array}{c} \text{NHC} \end{array}_{(CH_2)}^n \text{COH} \quad \text{or} \quad \begin{array}{c} \text{N} \end{array} \quad \text{C=S} \); 

\( X \) is a member selected from the group consisting of \( \begin{array}{c} \text{H}, \quad \text{OH} \quad \text{or} \quad \text{NHC}-(CH_2)-\text{COH}; \text{ and} \quad \begin{array}{c} \text{Z} \end{array} \quad \text{is a member of the group consisting of} \quad \begin{array}{c} \text{H} \quad \text{or} \quad \text{OH}, \end{array} \) 

with the proviso that when \( Y \) is \( \text{H} \), \( Z \) must also be \( \begin{array}{c} \text{H} \quad \text{and} \quad X \end{array} \) must be \( \text{NHC}-(CH_2)_{n} \text{COH} \), when \( X \) is \( \text{OH} \), \( Z \) must be \( \text{H} \) and \( Y \) must be \( \begin{array}{c} \text{H} \quad \text{N} \quad \text{C=S} \), and when \( Z \) is \( \text{OH} \), \( X \) must be \( \text{H} \) and \( Y \) must be \( \begin{array}{c} \text{H} \quad \text{N} \quad \text{C=S} \); 

and where \( n \) is an integer of 2 to 6.

Preferably \( n \) is an integer of 2 or 3 and the \( \begin{array}{c} \text{C}-(CH_2)_{n} \text{C} \) portion of the spacer is derived from succinic or glutaric anhydride.

The intermediates described by the above formula may be broken down into two subgroups.

The first subgroup is the glucosamine derivatives wherein \( Z \) is \( \text{H} \), \( Y \) is \( \text{H} \) and \( X \) is \( \text{NHC}-(CH_2)_{n} \text{COH} \), wherein \( n \) is an integer of 2 to 6.
The second subgroup is the N-succinyl or N-glutaryl-amido-phenyl-α-D-gluco- and mannopyranosides and the p-isothiocyanatophenyl-α-D-gluco- and mannopyranosides wherein X and Z are different and are selected from the group consisting of -H and -OH and Y is a member selected from the group consisting of

![Chemical Structure](image)

and n is an integer of 2 to 6.

The starting materials for the preparation of the sugar plus spacer glycocylated intermediates are glucosamine and p-nitrophenyl-α-D-gluco- and mannopyranosides and are commercially available.

The glucosamine may be reacted directly with an acid anhydride. Since the preferred spacers are succinyl and glutaryl moieties, the remainder of the discussion will be directed toward these derivatives. However, by appropriate synthesis, the 4 corresponding derivatives from adipic, pimelic and suberic acids may also be utilized.

The p-nitrophenyl-α-D-gluco- and mannopyranosides are first treated to reduce the nitro group to an amino group. They may then be reacted with succinic and glutaric anhydrides to produce the corresponding N-succinyl- and N-glutaryl derivatives.

The p-aminophenyl-α-D-gluco- and mannopyranosides may also be reacted with thiophosgene to form the corresponding p-isothiocyanatophenyl-α-D-gluco- and mannopyranosides. The synthesis of these products are detailed in the examples which follow.
The glycosylated intermediates which follow are representative of the novel pyranosides which may be used to couple with insulin.

n=2  N-succinyl glucosamine  mp  174-175°C
n=3  N-glutaryl glucosamine  mp  195-196°C

n=2  p-(succinylamido)-phenyl-\(\alpha\)-D-glucopyranoside  
     mp  178-180°C
n=3  p-(glutarylamido)-phenyl-\(\alpha\)-D-glucopyranoside  
     mp  167-168°C
1  n=2  p-(succinylamido)-phenyl-α-D-mannopyranoside
   mp  65-66°C
n=3  p-(glutarylamido)-phenyl-α-D-mannopyranoside
   mp  134-136°C

5

\[
\begin{array}{c}
\text{CH}_2\text{OH} \\
\text{H} & \text{H} & \text{O} & \text{N=C=S} \\
\text{HO} & \text{OH} & \text{HO} \\
\text{H} & \text{H} \\
\end{array}
\]

10  p-isothiocyanotophenyl-α-D-glucopyranoside

\[
\begin{array}{c}
\text{CH}_2\text{OH} \\
\text{H} & \text{H} & \text{O} & \text{N=C=S} \\
\text{HO} & \text{OH} & \text{HO} \\
\text{H} & \text{H} \\
\end{array}
\]

p-isothiocyanotophenyl-α-D-mannopyranoside

The structure of the insulin molecule is well known.

It consists of two polypeptide chains A and B linked
together by disulfide bonds of cystine. The N terminal
group of the A fraction is glycine (Gly A-1) and the
N-terminal group of the B fraction is phenylalanine (Phe
B-1). Both N-terminal positions contain reactive free

\( \alpha \)-amino groups. Adjacent the C-terminal group of the B
fraction is lysine having a free (\( \epsilon \)-amino group. It is
believed that these free amino groups contribute to the
problem of aggregation of insulin molecules with their
eventual precipitation.

By blocking these groups with the above glycosylated
intermediates, it was believed that the bioactivity of
the insulin would not be greatly affected and that aggregation could be significantly inhibited or prevented. In addition, it is believed that glycosylated insulins may have other properties which may contribute to a chemical-sustained release mechanism for delivery of insulin to a diabetic in direct response to a change in blood sugar levels without the need for external or implanted sensing devices.

The reaction of the intermediates shown above was carried out by conversion of the carboxylic acid at the end of the spacer to a mixed anhydride through reaction with an alkylchloroformate and reaction of the mixed anhydride with the native insulin. The mixed anhydride reacts with one or more of the A-1, B-1 or B-29 free amino groups on the insulin to form a mono-, di- or triglycosylated insulin via an amide linkage. The degree of substitution will depend on the molar ratio of intermediate to insulin and on reaction condition including pH. Generally, the molar ratio of intermediate to insulin will vary from 2 to 10. For purposes of reaction, a pH range of about 8 to 9.5 is preferable.

Because of the complexity of the reaction, one will seldom produce the glycosylated insulin as a mono-, di- or trisubstituted derivative. Rather, a mixture will be obtained as shown in the following examples.

For purposes of description, the glycosylated insulins may be divided into three categories.

The first category is those insulins prepared from glucosamines having a -C(CH$_2$)$_n$-C- spacer and possessing the general formula
wherein \( n \) is an integer of 2 to 6, \( m \) is an integer of 1 to 3 and wherein the glycosyl group is attached to the insulin through one or more of the \( \alpha \)-amino groups of the A-1 glycine, B-phenylalanine or \( \epsilon \)-amino group of the B-29 lysine moieties of the insulin molecule.

Representative insulins are \((\text{glucosamidosuccinyl}-)_m\) insulin and \((\text{glucosamidoglutaryl}-)_m\) insulin. A second category encompasses the gluco- and mannopyranosides coupled with a \( \overset{\text{O}}{\text{NH-}} \overset{\text{O}}{-\text{C-(CH}_2)_n\text{-C-}} \) spacer having the general formula

wherein \( X \) and \( Z \) are different and are selected from the group consisting of \(-\text{H} \) and \(-\text{OH} \), \( n \) is an integer of 2 to 6
and m is an integer of 1 to 3, and wherein each glycosyl group is attached to the insulin by an amide linkage through one or more of the \( \alpha \)-amino groups of the A-1 glycine, B-1 phenylalanine or \( \epsilon \)-amino group of the B-29 lysine moieties of the insulin molecule.

Representative compounds include \([p-(\alpha-D\text{-glucopyranosyloxy})\text{-phenyl-N-succinamyl}]_{m}\) insulin; \([p-(\alpha-D\text{-glucopyranosyloxy})\text{-phenyl-N-glutaramyl}]_{m}\) insulin; \([p-(\alpha-D\text{-mannopyranosyloxy})\text{-phenyl-N-succinamyl}]_{m}\) insulin; and \([p-(\alpha-D\text{-mannopyranosyloxy})\text{-phenyl-N-glutaramyl}]_{m}\) insulin.

The third category is inclusive of gluco- and mannopyranosides coupled with a \( \text{NHC}^\text{S} \) spacer having the general formula

\[
\begin{align*}
\text{CH}_2\text{OH} & \quad \text{OH} \\
\text{H} & \quad \text{Z} \\
\text{H} & \quad \text{X} \\
\text{HO} & \quad \text{NH-C}^\text{S} \\
\text{H} & \quad m
\end{align*}
\]

wherein Z and X are different and are selected from the group consisting of \(-\text{H}\) and \(-\text{OH}\), and m is an integer of 1 to 3 and wherein each glycosyl group is attached to the insulin by a thioamide linkage through one or more of the \( \alpha \)-amino groups of the A-1 glycine, B-1 phenylalanine or \( \epsilon \)-amino groups of the B-29 lysine moieties of the insulin molecule.
Representative compounds include [p-(α-D-glucopyranosyloxy)-phenyl-thiocarbamoyl-]ₘ insulin and [p-(α-D-mannopyranosyloxy)-phenyl-thiocarbamoyl-]ₘ insulin.

The glycosylated insulins prepared according to this invention may be administered to a diabetic in any conventional manner, i.e., subcutaneous, intramuscular or intraperitoneal injection. The dosage may be the same in terms of IU (international units) as will free or native insulin. Since dosages vary widely according to the needs of the patient, no attempt will be made to try to define dosage ranges. That will be left to the judgment of the patient's physician. Generally, dosages of 2 mg of insulin per day are required for a 60 Kg. man.

The following examples show the preparation of the intermediate compounds, the preparation of glycosylated insulins, their bioactivity and ability to inhibit or prevent aggregation.

**EXAMPLE I:**

Preparation of N-succinyl glucosamine

Glucosamine hydrochloride (0.05 m, 10.78 g) was dissolved in 15 mls of double distilled water and 0.05 m triethylamine (6.95 ml). To this was added, with stirring, succinic anhydride (0.05 m, 5.705 g) in 37.5 ml of acetone. The resulting mixture separated into two phases and sufficient water was added to bring both phases into a single solution. The solution was held at room temperature for four (4) hours for the reaction to be completed after which it was placed in a vacuum chamber and evaporated until a viscous, yellowish concentrated solution was obtained. The concentrate was measured and diluted with a triple amount of glacial
acetic acid resulting in the formation of a white precipitate of N-succinyl glucosamine. The product was separated from the acetic acid solution by filtration and washed with ethanol and then petroleum ether. The yield of the resulting product was 39%. The product had a melting point of 174-175°C and a molecular weight within 2.5% of the calculated mole weight of 279.26. The structure and molecular weight were confirmed by IR, NMR and MS/GC spectra.

EXAMPLE II:
Preparation of N-glutaryl glucosamine
The procedure of Example I was followed using glutaric anhydride. The product yield was 41%. The melting point was 195-196°C. The calculated mole weight was 293.27. Structure was confirmed by IR and NMR spectra.

EXAMPLE III:
Preparation of p-(succinylamido)-phenyl-α-D-glucopyranoside
In a first step, p-nitrophenyl-α-D glucopyranoside (14 m mole, 4.214 g) in 350 ml of methanol was reduced by mixing with ammonium formate (56 m mole, 3.54 g) and palladium on carbon particles at 25°C. The system was flushed for four (4) hours with nitrogen after which it was filtered and the filtrate was evaporated at a reduced pressure. The crude p-aminophenyl-α-D-glucopyranoside was purified by recrystallization in an ethanol-water (50:1) mixture. The yield was 71%. Its melting point was 169-170°C. Structure and molecular weight were confirmed by IR and MS/GC spectra. The observed molecular weight was within 2.7% of the calculated mole weight of 271.27.
Following the procedure of Example I, p-aminophenyl-\(\alpha\)-D-glucopyranoside was reacted with succinic anhydride to produce p-(succinylamido)-phenyl-\(\alpha\)-D glucopyranoside in a yield of 53%. The melting point of the product was 178-180°C. Structure and molecular weight were confirmed by IR, NMR and MS/GC spectra. The observed molecular weight was within 2% of the calculated mole weight of 371.34.

**EXAMPLE IV:**

Preparation of p-(glutarylamido)-phenyl-\(\alpha\)-D-glucopyranoside

The procedure of Example III was followed using glutaric anhydride in the place of succinic anhydride. The p-(glutaryl-amido)-phenyl-\(\alpha\)-D glucopyranoside was produced in a yield of 63% and had a melting point of 167-168°C. Structure was confirmed by IR spectra and the calculated mole weight was 385.37.

**EXAMPLE V:**

Preparation of p-(succinylamido)-phenyl-\(\alpha\)-D-mannopyranoside

First, p-nitrophenyl-\(\alpha\)-D-mannopyranoside was reduced to p-aminophenyl-\(\alpha\)-D-mannopyranoside using the procedure outlined in Example III. The product yield was 91% and the product melted at 150-153°C. The structure was verified by IR spectra.

The p-aminophenyl-\(\alpha\)-D-mannopyranoside thus produced was reacted with succinic anhydride in the manner described in Example III to produce p-(succinylamido)-phenyl-\(\alpha\)-D-mannopyranoside having a melting point of 65-66°C in 67% yield. Structure and molecular weight were confirmed by IR, NMR and MS/GC spectra. The
observed molecular weight was within 2% of the calculated molecular weight of 371.34.

**EXAMPLE VI:**

Preparation of p-(glutarylamido)-phenyl-α-D-mannopyranoside

The procedure outlined in Example V was followed substituting glutaric anhydride for succinic anhydride. The resulting p-(glutarylamido)-phenyl-α-D-mannopyranoside melting at 134-136°C was produced in a yield of 75%. The calculated molecular weight was 385.37. Structure was confirmed by IR spectra.

**EXAMPLE VII:**

Preparation of p-isothiocyanotophenyl-α-D-glucopyranoside

To a solution of p-(aminophenyl)-α-D-glucopyranoside in 80% aqueous ethanol was added a molar excess of thiophosgene (CSCl₂). The reaction was carried out at room temperature and was complete in a manner of minutes. A crystalline product was obtained. The calculated mole weight was 313.3.

**EXAMPLE VIII:**

Preparation of p-isothiocyanotophenyl-α-D-mannopyranoside

The procedure of Example VII may be followed substituting p-(aminophenyl)-α-D-mannopyranoside for the corresponding glucopyranoside to produce p-isothiocyanatophenyl-α-D-mannopyranoside.

In confirming the synthesis of the above combinations of glucosamine or p-aminophenyl-α-D gluco- and mannopyranosides with succinic and glutaric anhydrides, the following tests were utilized. An infrared spectrophotometer (Beckman Microlab 620 MX
Computing Infrared Spectrophotometer) was utilized to determine the reaction between the amino group and the anhydride by detecting the presence of an amide bond. Samples were prepared as 0.5% (w/w) KBr pellets. The presence of the amino group prior to reaction was detected by the N-H bending vibration at 1650-1580 cm\(^{-1}\). The p-aminophenyl derivatives prepared by the reduction of the corresponding p-nitrophenyl derivatives did not show N-O stretching bands at 1580 cm\(^{-1}\) and 1330 cm\(^{-1}\) indicating that the reduction reaction was complete. The formation of the amide bond was shown by the presence of a C=O stretching band at 1660 cm\(^{-1}\) and a N-H bending mode at 1600 cm\(^{-1}\). A normal dimeric carboxylic C=O stretching band was also found at about 1725 cm\(^{-1}\). These data confirm a distinct amide band indicating the completion of the coupling reaction between the amino and dicarboxylic acid anhydride reactants.

The molecular weights were determined by MS/GC spectra using a LKB 9000S MS/GC spectrophotometer interfaced with a DEC PDP 11/34 computer. The volatility of the carbohydrate derivatives was enhanced by using trimethylsilyl derivatization of the hydroxyl and carboxylic acid groups. In all instances, the observed molecular weight of the trimethylsilyl derivatives was within 2.5% of the calculated theoretical values.

The presence of the \(-\text{NH}_2(\text{CH}_2)_2\text{COOH}\) moiety was confirmed by proton MNR spectra using a JOEL JNM-FX 270 Fourier Transform NMR spectrophotometer. The samples were dissolved in D\(_2\)O and sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) was used as an internal reference. For example, in the p-(succinylamido-
α-D-glucopyranoside, the proton signals of the methylene groups in the succinyl moiety was observed at $\delta = 2.71$ as a triplet. The peak area was proportional to the number of protons representing the four methylene protons of the succinyl moiety.

The melting points were determined by the capillary melting point method.

The yield of the above glucose and mannose derivatives with the dicarboxylic acid anhydrides varied between about 39 and 91%. The variation in yield is thought to be due to the use of a limited solvent (ethanol-water mixture) for recrystallization. The yield should increase with the selection of a proper solvent for the recrystallization procedure.

The recoupling action of the above described glycosylamidocarboxylic acid derivatives with insulin is carried out via a mixed anhydride method wherein the mixed anhydride is not isolated from the reaction mixture. The glycosylamidocarboxylic acid is converted to mixed anhydride by reaction with isobutylchloroformate and the resulting mixed anhydride is reacted with a free amino group from the insulin molecule to form an amide linkage. The procedure is described in general by Erlanger et al in J. Biol. Chem., 228, 713 (1957) and Arekatsu et al in J. Immunal., 97, 858 (1966).

There are three primary sites available on the insulin molecule for reaction with the glycosylamidocarboxylic acid derivatives and the insulin may be coupled with one, two or three of these derivatives. These available sites include the α-amino groups of the glycine (Gly A-1), and phenylalanine (Phe B-1) and the ε-amino group of the lysine (Lys B-29) portions of the
insulin molecule. The pKapp values of these groups are:

8.0 for Gly A-1, 6.7 for Phe B-1 and 11.2 for Lys B-29.

Because insulin becomes denatured at too high a pH
and to maintain the ε-amino group of the Lys B-29 moiety
in a less reactive protonated state, the pH of the
coupling reaction between the glycosyl-amido-carboxylic
acids and insulin was chosen to be between 7.5 and 10 and
preferably at 9.5. Therefore, the ε-amino groups of the
Gly A-1 and Phe B-1 positions are thought to be the
primary reaction sites. However, trisubstituted
glycosylated insulin may also be produced by the above
method since a free ε-amino group from the Lys B-29
moiety could be formed by deprotonation through the use
of the highly nucleophilic tri-N-butylamine added to
complex the HCl produced during the anhydride formation
by the isobutylchloroformate. Also, based on the
Henderson-Hasselbach equation, at a pH of 9.5, about 2%
of the ε-amino groups of Lys B-29 exist in equilibrium in
the free or deprotonated form. Therefore, a significant
amount of trisubstituted glycosylated insulin may be
prepared. However, because of the pH chosen, i.e., 9.5
and the more reactive free amino groups of Gly A-1 and
Phe B-1 at that pH, the glycosylated insulin will be
primarily a mixture of di and tri-substituted
derivatives. Some monosubstitution may also be present.

In the following examples, the unreacted insulin is
removed from the glycosylated insulin by means of
affinity chromatography using a column containing
Sepharose beads bound with Con-A (Concanavalin-A).

It is known that Con-A has a binding affinity for
saccharides. Therefore, the more glycosyl moieties
coupled to the insulin, the greater that glycosylated
insulin will be bound to the Con-A in the chromatography column. One would then expect the unreacted insulin to be eluted through the column first followed by mono-, di- and tri-glycosylated insulins in that order.

This is generally true. However, some glycosylated derivatives may be eluted from the column along with unreacted insulin.

The following example is typical of the process of separating unreacted insulin from glycosylated insulin by affinity chromatography with Con-A.

EXAMPLE IX:

Preparation of N-succinylglucosamine

Coupled Insulin (Glucosaminosuccinyl Insulin)

Bovine insulin (87.77 μ moles 500 mg) was dissolved in 200 mls of an equal volume mixture of distilled water and dimethylformamide (DMF) and adjusted to a pH of 9.5 with 0.1 N sodium hydroxide and was then cooled in an ice bath. N-succinylglucosamine, (800 μ moles) was dissolved in a solution of DMF containing 800 μ moles each of tri-N-butylamine and isobutylchloroformate and kept at 0°C for 20 minutes. An additional 1.6 m mole of tri-N-butylamine was added to this solution which was then mixed, with stirring, to the insulin solution. The reaction mixture thus formed was pH adjusted to 9.5 with 0.1 N sodium hydroxide and kept for one hour at 0°C. The mixture was then kept at room temperature overnight and then dialyzed through a semipermeable membrane for two days against distilled water to remove unreacted N-succinylglucosamine. The distilled water was maintained at 4°C and was changed every four hours.

The glycosylated insulin remaining inside the dialysis membrane was lyophilized and dissolved in the
tris-buffer solution described below. The resulting solution was sterilized by filtration to remove any bacteria present.

The sterilized product was placed on a 2.5 X 60 cm column containing beads of commercial Con A (Concanavalin-A) bound to Sepharose 4B (Sigma Chemical Co., St. Louis, Mo.). The unreacted insulin was removed from the column using a 0.02 m tris-buffer eluent also containing 1mm MnCl₂, 1mm CaCl₂ and 0.5 m NaCl.

The eluent had a pH of 7.4 and was maintained at 4°C. The flow rate was maintained at 72 ml/hr and 7.0 ml fractions were collected and analyzed by UV spectra at 276 nm for the presence of insulin. A colorimetric determination for sugars at 480 nm using a phenol-sulfuric test also showed the presence of some N-succinylglucosamine coupled insulin.

After approximately 105 minutes as shown by FIG. 1, all of the unreacted insulin (component 1) had been collected as monitored by the UV spectra at 276 nm. At that time, 0.1m α-methyl-D-mannopyranoside was added to the tris-buffer solution as an eluent and the flow rate was maintained at 72 ml/hr. After approximately 200 minutes, all of component 2, consisting of N-succinylglucosamine, coupled insulin, had been collected as also shown in FIG. 1.

The low intrinsic binding capacity of the glucosamine moiety to Con-A was thought to be responsible for the mixed elution of free insulin and glycosylated insulin in component 1. Due to the low absorptivity of the glycosylated insulin in Component 2 at 480 nm, the degree of substitution could not be determined.
The glycosylated insulin in component 2 was lyophilized for determination of its ability to depress blood sugar levels. The corresponding N-glutarylglucosamine coupled insulin (glucosaminoglutaryl insulin) was prepared in a similar manner.

EXAMPLE X:
Preparation of p-(succinylamido)-phenyl-α-D-glucopyranoside Coupled Insulin

[p-(α-D-glucopyranosyloxy)-phenyl-N-succinamyl insulin]

The procedure of Example IX was followed for reacting the p-(succinylamido)-phenyl-α-D-glucopyranoside from Example III with bovine insulin. The results are shown in FIG. 2. Component 1 in FIG. 2 consisted of free insulin and some glycosylated insulin as verified by the phenol-sulfuric acid method at 480 nm. Components 2 and 3 were collected and tested by the phenol-sulfuric acid method for the presence of the glycosyl radical as well as at 276 nm for insulin. Due to the large amount of eluent required to separate component 3, it can be predicted that Component 3 contained more glycosyl radicals on the insulin than Component 2. The area under the curves of Components 2 and 3 was 58.9% and 41.1% respectively. Component 2 was primarily diglycosyl substituted insulin and Component 3 was primarily the triglycosyl substituted derivative. Therefore, 0.589 X 2 + 0.411 X 3 = 2.411 which would be the average number of glycosyl derivatives on the insulin contained in Components 2 and 3 combined. This degree of substitution was consistent with the phenol-sulfuric acid test which showed 2.3 glycosyl groups per insulin molecule. The
phenol-sulfuric acid test is detailed by Dubois et al., *Analytical Chemistry*, 28, 350 (1956).

After collection Components 2 and 3 were combined and dialyzed to remove the eluent, α-methyl-D-mannopyranoside, the purified product was lyophilized for biological testing.

Following the same procedure, the corresponding p-(glutarylamido)-phenyl-α-D-glucopyranoside coupled insulin [p-α-D-glucopyranosyloxy]-phenyl-N-glutaramyl insulin] was prepared.

**EXAMPLE XI:**

Preparation of p-(succinylamido)-phenyl-α-D-mannopyranoside Coupled Insulin

[p-(α-D-mannopyranosyloxy)-phenyl-N-succinamyl insulin]

The procedure outlined in Example X was followed and the elution profile is shown in FIG. 3. Component 1 was unreacted free insulin since the phenol-sulfuric acid test was negative. The average degree of glycosyl radicals attached to insulin for the combination of components 2 and 3 was 2.5 according to the phenol-sulfuric acid test. The area under the curves for components 2 and 3 was 34% and 66% respectively indicating an average degree of substitution of 2.66 which compares closely with the above test results.

The purified lyophilized product was retained for testing for blood sugar reduction.

The corresponding p-(glutarylamido)-phenyl-α-D-mannopyranoside coupled insulin [p-(α-D-mannopyranosyloxy)-phenyl-N-glutaramyl insulin] was prepared and purified by the above procedures.
EXAMPLE XII:

Preparation of p-(α-D-glucopyranosyloxy)-phenyl-thiocarbamoyl Insulin

p-(Isothiocyanotophenyl)-α-D-glucopyranoside (355.08 µ moles) from Example VII was dissolved in a solution of three parts pyridine and one part water at 5°C and the pH was adjusted to 8.0 with 0.1 N NaOH. Bovine insulin (177.54 µ moles, 1 gm) was prepared using a pyridine-water solvent and combined with the glucopyranoside solution. The combined solutions were maintained at 5°C at a pH of 8.0 for one hour and then allowed to stand overnight at room temperature. The reaction product consisting of p-(α-D-glucopyranosyloxy)-phenyl-thiocarbamoyl insulin was then dialyzed as in Example IX to remove unreacted p-(isothiocyanotophenyl)-α-D-glucopyranoside and the remaining product was lyophilized, dissolved in tris-buffer and subjected to affinity chromatography on a Con-A Sephrose 4B column as in Example IX. The flow rate was 26 ml/hr at 4°C and 5.0 ml fractions were collected. The elution profile is shown in FIG. 4. Component 1 contained both free insulin and glycosylated insulin and Component 2 consisted of p-(α-D-glucopyranosyloxy)-phenyl-thiocarbamoyl insulin having an average of 1.5 glycosyl groups per insulin molecule.

The product from component 2 was dialyzed to remove the α-methyl-D-mannopyranoside eluent and was then lyophilized for biological testing.

EXAMPLE XIII:

Aggregation Studies

One of the problems associated with free or native insulin is its tendency to aggregate and eventually crystallize out of solution, thereby reducing its bioavailability. With the glycosylated insulins this
tendency is greatly reduced since portions of the active amino sites on the Gly A-1, Phe B-1 and Lys B-29 in insulin are blocked by the coupling reaction of glycosyl groups.

Bulk aggregation studies with free insulin compared with glycosylated insulins were carried out by two methods. In a bulk aggregation study, various aqueous insulin and glycosylated insulin solutions containing 0.1 mg/ml of insulin were stirred at 1555 rpm until aggregation was visually observed or up to two weeks. In a second test, solutions containing the same insulin concentration were deposited on polyurethane (Biomer) and microscopically observed for aggregation.

The results are as follows:

<table>
<thead>
<tr>
<th>Aggregation Test</th>
<th>Glycosylated Insulins</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Free Insulin</td>
</tr>
<tr>
<td>Bulk</td>
<td>2 - 3 days</td>
</tr>
<tr>
<td>Polyurethane</td>
<td>1 - 2 days</td>
</tr>
</tbody>
</table>

A = \( p(\alpha-D\text{-glucopyranosyloxy})\)-phenyl-N-succinamyl insulin
B = \( p(\alpha-D\text{-mannopyranosyloxy})\)-phenyl-N-succinamyl insulin
C = \( p(\alpha-D\text{-glucopyranosyloxy})\)-phenyl-thiocarbamoyl insulin

It is obvious from the above results that the glycosylated insulins are much more stable against aggregation than free insulin and will thus have a better storage life.

EXAMPLE XIV:

Bioactivity of Glycosylated Insulins

The bioactivity of the glycosated insulins described herein was determined by a blood sugar depression test.
and compared to commercial insulin preparations and controls. In this test, replicates of standard laboratory rats were fasted for twenty hours. After measuring baseline blood sugar levels, a 1 mg/kg dose of either free or glycosylated insulin was injected via an intraperitoneal route. The blood sugar level in each rat was measured colorimetrically 20 minutes after the injection. The results are given in the following table:
### BLOOD SUGAR DEPRESSION (BSD) TEST

<table>
<thead>
<tr>
<th>Type of Insulin</th>
<th>No. Rats</th>
<th>Blood Sugar Concentration after 20 min. IP. injection (± S.E.M.) mg/dl</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIGMA INS. (21F-0375)25.5IU/MG.</td>
<td>5</td>
<td>32.66 ± 1.10</td>
</tr>
<tr>
<td>LILLY INS (615-70N-80)100IU/MG.</td>
<td>5</td>
<td>31.87 ± 1.93</td>
</tr>
<tr>
<td>Glucosaminosuccinyl insulin (unpruified)</td>
<td>5</td>
<td>37.80 ± 1.13</td>
</tr>
<tr>
<td>Glucosaminoslutaryl insulin (unpurified)</td>
<td>4</td>
<td>45.92 ± 3.30</td>
</tr>
<tr>
<td>p-(α-D-glucopyranosyloxy)-phenyl-N-succinamyl insulin</td>
<td>5</td>
<td>40.87 ± 1.32</td>
</tr>
<tr>
<td>p-(α-D-glucopyranosyloxy)-phenyl-N-glutaramyl insulin</td>
<td>5</td>
<td>40.40 ± 2.53</td>
</tr>
<tr>
<td>p-(α-D-mannopyranosyloxy)-phenyl-N-succinamyl insulin</td>
<td>5</td>
<td>44.80 ± 2.37</td>
</tr>
<tr>
<td>p-(α-D-mannopyranosyloxy)-phenyl-N-glutaramyl insulin</td>
<td>5</td>
<td>40.60 ± 0.80</td>
</tr>
<tr>
<td>p-(α-D-glucopyranosyloxy)-phenyl-Thiocarbamoyl insulin</td>
<td>5</td>
<td>44.67 ± 2.21</td>
</tr>
<tr>
<td>Control</td>
<td>*44</td>
<td>64.62 ± 0.61</td>
</tr>
</tbody>
</table>

*Includes all rats used in test at baseline level*
It is evident from the above that the seven glycosylated insulins prepared, as described herein, all possess significant biological activity in depressing blood sugar levels.
1. A compound of the formula

\[
\begin{align*}
\text{CH}_2\text{OH} & \\
\text{H} & \\
\text{H} & \\
\text{H} & \\
\text{H} & \\
\text{H} & \\
\text{OY} & \\
\text{X} & \\
\end{align*}
\]

wherein \(Y\) is a member selected from the group consisting of \(H\), \(-\text{NHC-}(\text{CH}_2)_n\text{COH}\) or \(-\text{N}=\text{C}=\text{S}\); \(X\) is a member of the group consisting of \(-H\), \(-OH\) or \(-\text{NHC-}(\text{CH}_2)_n\text{COH}\); and \(Z\) is a member of the group consisting of \(-H\) or \(-OH\), with the proviso that when \(Y\) is \(-H\), \(Z\) must also be \(-H\) and \(X\) must be \(-\text{NHC-}(\text{CH}_2)_n\text{COH}\), when \(X\) is \(-OH\), \(Z\) must be \(-H\) and \(Y\) must be \(-\text{NHC-}(\text{CH}_2)_n\text{COH}\) or \(-\text{N}=\text{C}=\text{S}\), and when \(Z\) is \(-OH\), \(X\) must be \(-H\) and \(Y\) must be \(-\text{NHC-}(\text{CH}_2)_n\text{COH}\) or \(-\text{N}=\text{C}=\text{S}\);

and where \(n\) is an integer of 2 to 6.

2. A compound according to Claim 1 wherein \(Z\) is

\[
\begin{align*}
\text{CH}_2\text{OH} & \\
\text{H} & \\
\text{H} & \\
\text{H} & \\
\text{H} & \\
\text{H} & \\
\text{OY} & \\
\text{X} & \\
\end{align*}
\]

wherein \(Y\) is \(-H\) and \(X\) is \(-\text{NHC-}(\text{CH}_2)_n\text{COH}\); wherein \(n\) is an integer of 2 to 6.
3. A compound according to Claim 2 wherein n is 2 and having the formula

4. A compound according to Claim 2 wherein n is 3 and having the formula
5. A compound according to Claim 1 wherein X and Z are different and are selected from the group consisting of -H and -OH and Y is a member selected from the group consisting of \[ \text{O} \quad \text{O} \]
\[ \text{NHC(CH}_2\text{)}_n\text{COH} \quad \text{N=C=S, and n} \]
is an integer of 2 to 6.

6. A compound according to Claim 5 wherein Z is -H, X is -OH and Y is \[ \text{NHCCH}_2\text{CH}_2\text{COH}. \]

7. A compound according to Claim 5 where Z is -H, X is -OH and Y is \[ \text{NHCCH}_2\text{CH}_2\text{COH}. \]

8. A compound according to Claim 5 where Z is -H, X is -OH and Y is \[ \text{N=C=S}. \]

9. A compound according to Claim 5 wherein Z is -OH, X is -H and Y is \[ \text{NHCCH}_2\text{CH}_2\text{COH}. \]

10. A compound according to Claim 5 wherein Z is -OH, X is -H and Y is \[ \text{NHCCH}_2\text{CH}_2\text{COH}. \]

11. A compound according to Claim 5 wherein Z is -OH, X is -H and Y is \[ \text{N=C=S}. \]
12. A glycosylated insulin having the formula

\[
\begin{align*}
\text{CH}_2\text{OH} \\
\text{H} \quad \text{H} \\
\text{OH} \quad \text{OH}
\end{align*}
\]

\[
\underbrace{\text{NH-C(H}_2)_n\text{O}}_{\text{m}}
\]

wherein \( n \) is an integer of 2 to 6, \( m \) is an integer of 1 to 3 and wherein the glycosyl group is attached to the insulin through one or more of the \( \alpha \)-amino groups of the A-1 glycine, B-1 phenylalanine or \( \zeta \)-amino group of the B-29 lysine moieties of the insulin molecule.

13. A glycosylated insulin according to Claim 12 wherein \( n \) is 2.

14. A glycosylated insulin according to Claim 12 wherein \( n \) is 3

15. A glycosylated insulin having the formula

\[
\begin{align*}
\text{CH}_2\text{OH} \\
\text{H} \quad \text{H} \\
\text{OH} \quad \text{OH} \quad \text{X}
\end{align*}
\]

\[
\underbrace{\text{NH-C(H}_2)_n\text{O}}_{\text{m}}
\]

wherein \( X \) and \( Z \) are different and are selected from the group consisting of \(-\text{H} \) and \(-\text{OH} \), \( n \) is an integer of 2 to 6 and \( m \) is an integer of 1 to 3, and wherein each glycosyl group is attached to the insulin by an amide linkage.
through one or more of the α-amino groups of the A-1 glycine, B-1 phenylalanine or ε-amino group of the B-29 lysine moieties of the insulin molecule.

16. A glycosylated insulin according to Claim 15 wherein Z is -H, X is -OH and n is 2.

17. A glycosylated insulin according to Claim 15 wherein Z is -H, X is -OH and n is 3.

18. A glycosylated insulin according to Claim 15 wherein Z is -OH, X is -H and n is 2.

19. A glycosylated insulin according to Claim 15 wherein Z is -OH, X is -H and n is 3.

20. A glycosylated insulin having the formula

![Chemical Structure](image)

wherein Z and X are different and are selected from the group consisting of -H and -OH, and m is an integer of 1 to 3 and wherein each glycosyl group is attached to the insulin by thioamide linkage through one or more of the α-amino groups of the A-1 glycine, B-1 phenylalanine or ε-amino group of the B-29 lysine moieties of the insulin molecule.

21. A glycosylated insulin according to Claim 20 wherein Z is -H and X is -OH.
22. A glycosylated insulin according to Claim 20 wherein Z is \(-\text{OH}\) and X is \(-\text{H}\).

23. A method of depressing the blood sugar level in a diabetic patient which comprises administering to said patient an effective predetermined amount of a glycosylated insulin of the formula

\[
\text{insulin}
\]

wherein \(n\) is an integer of 2 to 6, \(m\) is an integer of 1 to 3 and wherein the glycosyl group is attached to the insulin by an amide linkage through one or more of the \(\alpha\)-amino groups of the A-1 glycine, B-1 phenylalanine, or \(\epsilon\)-amino group of the B-29 lysine moieties of the insulin molecule, in a pharmaceutically acceptable carrier.

24. A method according to Claim 23 wherein the effective amount of the glycosylated insulin has been determined based upon the needs of the patient.

25. A method according to Claim 24 wherein \(n\) is 2.

26. A method according to Claim 24 wherein \(n\) is 3.

27. A method of depressing the blood sugar level in a diabetic patient which comprises administering to said patient, in a pharmaceutically acceptable carrier, an effective amount of a glycosylated insulin having the formula
wherein X and Z are different and are selected from the group consisting of -H and -OH, n is an integer of 2 to 6 and m is an integer of 1 to 3 and wherein each glycosyl group is attached to the insulin by an amide linkage through one or more of the α-amino groups of the A-1 glycine, B-1 phenylalanine or (L-amino group of the B-29 lysine moieties of the insulin molecule.

28. A method according to Claim 27 wherein the effective amount of the glycosylated insulin has been determined based upon the needs of the patient.

29. A method according to Claim 28 wherein Z is H, X is -OH and n is 3.

30. A method according to Claim 28 wherein Z is -H, X is -OH and n is 2.

31. A method according to Claim 28 wherein Z is -OH, X is -H and n is 2.

32. A method according to Claim 28 wherein Z is -OH, X is -H and n is 3.

33. A method of depressing the blood sugar level in a diabetic patient which comprises administering to said patient, in a pharmaceutically acceptable carrier, an effective amount of a glycosylated insulin having the formula
wherein Z and X are different and are selected from the group consisting of -H and -OH, and m is an integer of 1 to 3 and wherein each glycosyl group is attached to the insulin by a thioamide linkage through one or more of the α-amino groups of the A-1 glycine, B-1 phenylalanine or ε-amino group of the B-29 lysine moieties of the insulin molecule.

34. A method according to Claim 33 wherein the effective amount of the glycosylated insulin has been determined based upon the needs of the patient.

35. A method according to Claim 34 wherein Z is -H and X is -OH.

36. A method according to Claim 34 wherein Z is -OH and X is -H.
**INTERNATIONAL SEARCH REPORT**

International Application No PCT/US83/01780

**I. CLASSIFICATION OF SUBJECT MATTER**

According to International Patent Classification (IPC) or both National Classification and IPC

<table>
<thead>
<tr>
<th>Int.Cl.</th>
<th>A61K 37/26; C07C 103/52; C07G 7/00; C07G 11/00; C08B 37/00</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. Cl.</td>
<td>424/178; 260/112.7; 536/17.2; 536/17.5; 536/53</td>
</tr>
</tbody>
</table>

**II. FIELDS SEARCHED**

Minimum Documentation Searched

<table>
<thead>
<tr>
<th>Classification System</th>
<th>Classification Symbols</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>424/178; 260/112.7; 536/17.2; 536/17.5; 536/53</td>
</tr>
</tbody>
</table>

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched

**III. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of Document, 12 with indication, where appropriate, of the relevant passages</th>
<th>Relevant to Claim No. 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US, A, 4,152,513, published 5 May 1983, Austin et al.</td>
<td>1-4</td>
</tr>
<tr>
<td>X</td>
<td>US, A, 3,591,574, published 7 July 1971, Fenichel et al.</td>
<td>1-4</td>
</tr>
</tbody>
</table>

* Special categories of cited documents: 14

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "A" document member of the same patent family

**IV. CERTIFICATION**

Date of the Actual Completion of the International Search 1 

1 FEBRUARY 1984

International Searching Authority 1

ISA/US

Date of Mailing of this International Search Report 3

14 FEB 1984

Signature of Authorized Officer 80

[Signature]

Primary Examiner

Form PCT/ISA/210 (second sheet) (October 1981)